IQV — IQVIA Holdings Inc.

The tape has turned decisively positive since the 2026-07-28 Q2 print: adjusted EPS beat, raised FY2026 guidance, record $3.15B R&D net new bookings (1.22x book-to-bill), and a $2.0B buyback. Institutional accumulation, including a large BlackRock stake, and a healthcare sector rally have pushed the stock to within ~1% of its 52-week high. As of 2026-08-27, the RSI of 73.31 and price 30.8% above its 200-day SMA show sentiment is extended, but the direction is clearly bullish.

Revenue growth has clearly accelerated: YoY growth was ~2.3% in Q4 2023/Q1 2024, 4–5% through mid-2025, then 8.4–8.7% in the first two quarters of 2026. Q2 2026 revenue was $4.37B, up 8.7% YoY. The operating story is a genuine inflection, helped by record R&D bookings ($3.15B, +19% YoY). GAAP operating margins in the last two reported quarters were 11.6% and 12.4%, a modest step-down from the year-earlier 12.6% and 12.9%, so growth is not yet translating into margin expansion; Q4 2025's 16.8% margin was an outlier likely distorted by one-offs. FCF in Q2 2026 was $360M, up 23% YoY, and TTM FCF is ~$2.0B, roughly flat year-over-year.

As of 2026-08-27, trailing GAAP P/E is 32.3x, below its own 5-year average of 35.4x; P/S is 2.54x vs. the 2.82x average. On 2026 adjusted EPS guidance of $12.80–$13.00, forward P/E is only ~20.2x—not expensive for a business growing revenue ~7% and adjusted EPS ~10%+. PEG of 1.96 on trailing numbers is fair-ish. The FMP consensus target of $237.38 sits below the current price, though brief-cited revisions to $277–$288 suggest that target is stale. On balance, valuation is reasonable-to-slightly-rich at the 52-week high, not a bargain.

The stock is pricing in continued high-single-digit revenue growth and disciplined margin/buyback-driven EPS growth. At ~$262, the market is paying ~20x forward adjusted earnings for a company that just posted record bookings and raised guidance—that is not a demanding ask if momentum holds. The playbook: if Q3 2026 shows bookings converting and margins stabilizing or expanding, earnings revisions should push the stock higher; if growth decelerates or staffing costs bite, the air pocket is toward the ~$237 consensus level and then the 50-day SMA (~$219).

As of 2026-08-27, RSI(14) is 73.31—overbought. Price is +7.1% above the 20-day SMA, +19.6% above the 50-day SMA, and +30.8% above the 200-day SMA, all in a steep uptrend just off the 52-week high. Momentum is strong, but chasing here has poor risk/reward; a pullback toward the 20-day (~$245) or 50-day (~$219) SMA would be a more attractive entry.

• Easing Treasury yields and healthcare sector strength (XLV at record highs) are supporting rate-sensitive, growth-oriented life sciences names.
• Biotech funding has stabilized, boosting CRO demand and client appetite for outsourced R&D.
• Pharma pricing pressure and R&D efficiency mandates favor IQVIA's data/analytics and decentralized trial offerings.
• Regulatory momentum for streamlined early clinical development could expand trial activity.
• High debt load (D/E 2.63, long-term debt $13.7B) makes IQV sensitive to interest-rate and refinancing conditions, even if cash flow is stable.

• Q3 2026 earnings (late Oct 2026): whether record $3.15B bookings convert into sustained revenue acceleration and stable margins.
• Continued execution of the $2.0B buyback—~6.8% of shares—through H2 2026.
• Further 2026 guidance raise or strong 2027 outlook on AI/data product momentum.
• Additional large institutional accumulation or strategic partnership wins in clinical decision support.

• Leverage: debt/equity 2.63 and current ratio 0.71 leave limited balance-sheet flexibility; rising rates or a cash-flow hiccup would hurt.
• Margin compression from clinical staffing/wage inflation and lower utilization—operating margins ticked down YoY in Q1/Q2 2026.
• Technical/valuation risk: RSI 73.31 and price 30.8% above the 200-day SMA leave little room for disappointment; the FMP consensus target is below spot.
• Cancellation or slowdown in biotech funding or pharma R&D spend would directly hit bookings and revenue.

IQVIA is a high-quality, competitively advantaged CRO/data business that is demonstrably inflecting—revenue growth has roughly doubled from early 2024 to Q2 2026 and bookings are at records. But the stock has already repriced that optimism to a 52-week high with overbought technicals and a consensus target below spot, so the risk/reward is balanced rather than compelling. I would be a buyer closer to the 50-day SMA, not at $262.38.

Using EV/EBITDA: 2026 guidance-adjusted EBITDA midpoint ~$4.025B × 14.5x (slightly above the current ~13.7x to reflect accelerating growth and record bookings) = ~$58.4B EV; subtract net debt (~$13.7B LT debt minus ~$1.9B cash ≈ $11.8B) and divide by ~164.6M shares = ~$283. Cross-check: roughly 22x 2026 adjusted EPS of ~$12.90 also gives ~$283.